La cadena de opciones muestra datos clave de las opciones de acciones de HUTCHMED (China) a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para HUTCHMED (China)..

HUTCHMED (China) (NASDAQ:HCM) Bolsa, Cadena de Opciones

HUTCHMED (China)

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM III Acquisition Corp

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Press Releases

UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

General

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

News

Health Care

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED to Announce 2025 Half-Year Financial Results

Earnings

HUTCHMED Reports 2025 Interim Results

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Management

HUTCHMED Announces Appointment of Acting Chief Executive Officer

ABBNY

BDOUY

BLTE

BVNRY

CLCGY

EPOAY

FPAFY

ICAGY

IFNNY

VIOT

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

Axsome Therapeutics

BGM Group

Bausch Health Companies Inc. Common Stock

Bausch Health Companies

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Indivior

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pharvaris

Perrigo

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Wave Life Sciences Ltd. - Ordinary Shares

Comments

HUTCHMED (China)

HUTCHMED (China) (HCM) Opciones

HUTCHMED (China) (NASDAQ:HCM) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL